-
Morsing Mahoney posted an update 3 weeks, 2 days ago
This study investigated the particle disintegration of cooked milled rice during in vitro digestion to identify its potential for rapidly predicting glycaemic index (GI). Milled grains and flour of rice with varying GI were cooked, stirred and subjected to digestion followed by kinetics analyses. Despite variations in physicochemical parameters (typically amylose content), flours showed a single-phase-digestion rate (k, ∼0.12 min-1) which did not vary significantly between varieties. ML-7 inhibitor In contrast, intact grains were disintegrated into small/intermediate (d 300 μm) particles. The small/intermediate particles comprising 50-70 % starch were initially-digested (0-20 min) at a fast k-f (∼0.05-0.10 min-1), which enabled to differentiate rice digestibility; whereas the large was latter-digested (20-180 min) at a slow k-s (∼0.04 min-1). The sum-ratio of disintegrated-particle 0-300 μm (Q-300) correlated positively with clinical GI values, allowing for a digestibility prediction of intact milled rice grain.In this study, a natural polymer-based organic flocculant (sodium alginate-methacrylatoethyl trimethyl ammonium chloride, SA-PDMC) was synthesized by graft copolymerization. The optimum preparation procedures were determined by single factor experiments. The flocculation behaviors of SA-PDMC were investigated in humic acid (HA) and kaolin suspension considering the effects of flocculant doses and initial pH. The results indicated that charge neutralization and bridging action played an important role in the removals of HA and kaolin. Also, SA-PDMC performed well in a wide pH range of 5.0-10.0. Besides, SA-PDMC, as polyaluminium (PAC) aid, was investigated in the lake water treatment. The ratio of PAC and SA-PDMC was optimized through response surface methodology based on a central composite design. Results showed that SA-PDMC and PAC have a strong synergy, under optimal conditions SA-PDMC can reduce the dose of PAC by 40 % while ensuring the water quality.
Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and the ability of ctDNA testing to select patients for mutation-directed therapy.
We did an open-label, multicohort, phase 2a, platform trial of ctDNA testing in 18 UK hospitals. Participants were women (aged ≥18 years) with histologically confirmed advanced breast cancer and an Eastern Cooperative Oncology Group performance status 0-2. Patients had completed at least one previous line of treatment for advanced breast cancer or relapsed within 12 months of neoadjuvant or adjuvant chemotherapy. Patients were recruited into four parallel treatment cohorts matched to mutations identified in ctDNA cohort A comprised patients with ESR1 mutations (treated with intramuscular extended-dose fulvestrant 500 mg); cohort B comprised patients with HER2 mutations (treated with oral neratieath caused by grade 4 dyspnoea (in cohort C).
ctDNA testing offers accurate, rapid genotyping that enables the selection of mutation-directed therapies for patients with breast cancer, with sufficient clinical validity for adoption into routine clinical practice. Our results demonstrate clinically relevant activity of targeted therapies against rare HER2 and AKT1 mutations, confirming these mutations could be targetable for breast cancer treatment.
Cancer Research UK, AstraZeneca, and Puma Biotechnology.
Cancer Research UK, AstraZeneca, and Puma Biotechnology.
Tumour mutational burden (TMB) has been retrospectively correlated with response to immune checkpoint blockade. We prospectively explored the association of high tissue TMB (tTMB-high) with outcomes in ten tumour-type-specific cohorts from the phase 2 KEYNOTE-158 study, which assessed the anti-PD-1 monoclonal antibody pembrolizumab in patients with selected, previously treated, advanced solid tumours.
In the multi-cohort, open-label, non-randomised, phase 2 KEYNOTE-158 study, patients were enrolled from 81 academic facilities and community-based institutions across 21 countries in Africa, the Americas, Asia, and Europe. Eligible patients were aged 18 years or older, had a histologically or cytologically confirmed advanced (ie, unresectable or metastatic, or both) incurable solid tumour (eligible tumour types were anal, biliary, cervical, endometrial, mesothelioma, neuroendocrine, salivary, small-cell lung, thyroid, and vulvar), progression on or intolerance to one or more lines of standard therapy, had me29%; 95% CI 21-39) of 102 patients in the tTMB-high group and 43 (6%; 5-8) of 688 in the non-tTMB-high group. 11 (10%) of 105 patients had treatment-related serious adverse events. 16 (15%) participants had a grade 3-5 treatment-related adverse event, of which colitis was the only such adverse event that occurred in more than one patient (n=2). One patient had fatal pneumonia that was assessed by the investigator to be treatment related.
tTMB-high status identifies a subgroup of patients who could have a robust tumour response to pembrolizumab monotherapy. tTMB could be a novel and useful predictive biomarker for response to pembrolizumab monotherapy in patients with previously treated recurrent or metastatic advanced solid tumours.
Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.
Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.
There is growing evidence of vaccine delays or refusals due to a lack of trust in the importance, safety, or effectiveness of vaccines, alongside persisting access issues. Although immunisation coverage is reported administratively across the world, no similarly robust monitoring system exists for vaccine confidence. In this study, vaccine confidence was mapped across 149 countries between 2015 and 2019.
In this large-scale retrospective data-driven analysis, we examined global trends in vaccine confidence using data from 290 surveys done between September, 2015, and December, 2019, across 149 countries, and including 284 381 individuals. We used a Bayesian multinomial logit Gaussian process model to produce estimates of public perceptions towards the safety, importance, and effectiveness of vaccines. Associations between vaccine uptake and a large range of putative drivers of uptake, including vaccine confidence, socioeconomic status, and sources of trust, were determined using univariate Bayesian logistic regressions.